Open AccessSyndrome of inappropriate antidiuretic hormone secretion as a side effect of chemotherapy for testicular cancer: A case report
Author(s) -
Maeda Koki,
Kageyama Susumu,
Osafune Takashi,
Masuda Yoshikata,
Nakagawa Shota,
Miki Kenji,
Esumi Shun,
KakitaKobayashi Maiko,
Yoshida Tetsuya,
Narita Mitsuhiro,
Kawauchi Akihiro
Publication year - 2019
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12122
Subject(s) - medicine , hyponatremia , etoposide , cisplatin , hypertonic saline , antidiuretic , bleomycin , syndrome of inappropriate antidiuretic hormone secretion , testicular cancer , chemotherapy , hormone
Inappropriate antidiuretic hormone secretion syndrome can be a serious adverse event of cisplatin‐based chemotherapy. Cisplatin had to be changed to other drugs or chemotherapy completely discontinued in earlier reported cases. Case presentation Three cycles of bleomycin, etoposide, and cisplatin chemotherapy were planned for a 40‐year‐old man with a diagnosis of lymph node recurrence of testicular cancer. On day 9, he suffered from vomiting and mental disturbance. Severe hyponatremia (110 mEq/L) with low plasma osmolality led to a diagnosis of a syndrome of inappropriate antidiuretic hormone secretion, and infusions of hypertonic saline and salt intake were prescribed. Second and third courses of bleomycin, etoposide, and cisplatin chemotherapy could then be given with careful electrolyte management. Conclusion Continuation of cisplatin administration with precise electrolyte adjustment can be a treatment option in regimens where cisplatin is essential for achieving optimal antitumor efficacy.